|
[1]
|
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Diabetes, Obesity and Metabolism,
2026
DOI:10.1111/dom.70291
|
|
|
|
|
[2]
|
De-escalation strategies in the management of differentiated thyroid cancer
Endocrine,
2026
DOI:10.1007/s12020-026-04563-1
|
|
|
|
|
[3]
|
Exploring Punicalagin Potential Against Cancers: A Comprehensive Review
Food Science & Nutrition,
2025
DOI:10.1002/fsn3.70072
|
|
|
|
|
[4]
|
Neomorphic IDH Heterodimer Mutants: An Underestimated Point in Cancer Pathogenesis
Current Cancer Drug Targets,
2025
DOI:10.2174/0115680096317314240723054739
|
|
|
|
|
[5]
|
A Hybrid Ensemble Framework for Binary Classification of Thyroid Recurrence Using SVM, XGBoost, and Gradient Boosting
2025 International Conference on Information, Implementation, and Innovation in Technology (I2ITCON),
2025
DOI:10.1109/I2ITCON65200.2025.11210629
|
|
|
|
|
[6]
|
The role of epigenetic methylations in thyroid Cancer
World Journal of Surgical Oncology,
2024
DOI:10.1186/s12957-024-03568-2
|
|
|
|
|
[7]
|
Female reproductive function after radioiodine therapy for differentiated thyroid carcinoma
Problems of Endocrinology,
2024
DOI:10.14341/probl13407
|
|
|
|
|
[8]
|
Papillary thyroid carcinoma associated with non‑functioning parathyroid carcinoma with Warthin's tumor of the parotid gland: A case report and brief literature review
Medicine International,
2023
DOI:10.3892/mi.2023.86
|
|
|
|
|
[9]
|
Marcadores moleculares para el diagnóstico de cáncer de tiroides
Anatomía Digital,
2023
DOI:10.33262/anatomiadigital.v6i4.3.2880
|
|
|
|
|
[10]
|
AGGRESSIVE COURSE OF DIFFERENTIATED THYROID GLAND CANCER IN A PATIENT WITH INSULIN RESISTANCE: CASE ANALYSIS FROM PRACTICE
Wiadomości Lekarskie,
2022
DOI:10.36740/WLek202211227
|
|
|
|